Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025

BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best high growth European stocks to buy. On January 7, Citizens reaffirmed its Market Outperform rating and $396 price target for BeOne Medicines Ltd. (NASDAQ:ONC), citing strong effectiveness results from a Phase 3 trial in gastric cancer patients. BeOne Medicines Ltd. (NASDAQ:ONC) and Jazz Pharmaceutics shared further findings from the HERIZON-GEA-01 trial, which revealed high efficacy in patients with advanced gastric or gastroesophageal adenocarcinoma (GEA).

Citizens observed that BeOne’s Brukinsa was on track to generate about $3.8 billion in revenue in 2025, thanks to an impressive development pipeline that includes numerous assets across diverse indications.

The company also revealed the first clearance for sonrotoclax, its next-generation BCL2 inhibitor, which Citizens anticipates could contribute to subsequent approvals worldwide.

At the same time, the firm emphasized BeOne’s $4.1 billion cash position and stated that the recent share price decline represented a “unique buying opportunity” in one of the world’s leading hematology/oncology companies.

BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.

While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.